← FDA DRUG APPROVALS

FDA ANDA · ANDA062544

DEXACIDIN

Sponsor: NOVARTIS

APPLICATION
ANDA062544
TYPE
ANDA
ORIGINAL APPROVAL
1984-10-29
LATEST ACTION
2001-04-19
ROUTE
OPHTHALMIC
DOSAGE FORM
SUSPENSION/DROPS
MARKETING STATUS
Discontinued

Products

DEXACIDINDiscontinued
DEXAMETHASONE 0.1%, NEOMYCIN SULFATE EQ 3.5MG BASE/ML, POLYMYXIN B SULFATE 10,000 UNITS/ML · SUSPENSION/DROPS · OPHTHALMIC

Approval history

2001-04-19Manufacturing (CMC) · Supplement 9AP
1998-02-11Manufacturing (CMC) · Supplement 6AP
1995-04-24Manufacturing (CMC) · Supplement 4AP
1994-06-10Manufacturing (CMC) · Supplement 5AP
1993-08-17Labeling · Supplement 3AP
1993-01-04Manufacturing (CMC) · Supplement 2AP
1984-10-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →